PE20250684A1 - Compuestos y metodos para el tratamiento de enfermedades - Google Patents

Compuestos y metodos para el tratamiento de enfermedades

Info

Publication number
PE20250684A1
PE20250684A1 PE2024001999A PE2024001999A PE20250684A1 PE 20250684 A1 PE20250684 A1 PE 20250684A1 PE 2024001999 A PE2024001999 A PE 2024001999A PE 2024001999 A PE2024001999 A PE 2024001999A PE 20250684 A1 PE20250684 A1 PE 20250684A1
Authority
PE
Peru
Prior art keywords
compound
diseases
compounds
treatment
methods
Prior art date
Application number
PE2024001999A
Other languages
English (en)
Spanish (es)
Inventor
Donna L Romero
Oliver Saunders
Gregory Stuart Bisacchi
Dennis Zaller
Rosana Kapeller-Libermann
Original Assignee
Rome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rome Therapeutics Inc filed Critical Rome Therapeutics Inc
Publication of PE20250684A1 publication Critical patent/PE20250684A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2024001999A 2022-03-15 2023-03-15 Compuestos y metodos para el tratamiento de enfermedades PE20250684A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263269375P 2022-03-15 2022-03-15
US202263354620P 2022-06-22 2022-06-22
US202263424723P 2022-11-11 2022-11-11
PCT/US2023/064373 WO2023178133A1 (en) 2022-03-15 2023-03-15 Compounds and methods for treating disease

Publications (1)

Publication Number Publication Date
PE20250684A1 true PE20250684A1 (es) 2025-03-04

Family

ID=88024390

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001999A PE20250684A1 (es) 2022-03-15 2023-03-15 Compuestos y metodos para el tratamiento de enfermedades

Country Status (13)

Country Link
US (3) US20230295212A1 (https=)
EP (1) EP4493573A1 (https=)
JP (1) JP2025509635A (https=)
KR (1) KR20250004956A (https=)
CN (1) CN119546620A (https=)
AU (1) AU2023236711A1 (https=)
CA (1) CA3245459A1 (https=)
CO (1) CO2024012882A2 (https=)
IL (1) IL315480A (https=)
MX (1) MX2024011291A (https=)
PE (1) PE20250684A1 (https=)
TW (1) TW202400134A (https=)
WO (1) WO2023178133A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025059461A1 (en) * 2023-09-14 2025-03-20 Rome Therapeutics, Inc. Crystalline compounds, pharmaceutical compositions, and methods for treating disease
WO2025255245A1 (en) * 2024-06-04 2025-12-11 Rome Therapeutics, Inc. Compounds and their use in treating medical conditions
WO2025255246A1 (en) * 2024-06-04 2025-12-11 Rome Therapeutics, Inc. Compounds and their use in treating medical conditions
CN121891392A (zh) * 2024-10-18 2026-04-21 河南真实生物科技有限公司 阿兹夫定类药物的制药用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JPH09328497A (ja) 1996-04-12 1997-12-22 Yamasa Shoyu Co Ltd ４’−フルオロメチルヌクレオシド
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
EP2180064A3 (en) 2000-10-18 2010-08-11 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
WO2002062197A2 (en) 2000-12-19 2002-08-15 Hospital For Special Surgery Markers for disease susceptibility and targets for therapy
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AU2003220277A1 (en) 2002-03-12 2003-09-29 The Johns Hopkins University School Of Medicine Manganese ion regulation of reverse transcriptase activity and methods of modulating same
WO2004000858A2 (en) 2002-06-21 2003-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20050113324A1 (en) 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20070281911A1 (en) 2004-01-21 2007-12-06 Gilead Sciences Inc. Use of Adefovir or Tenofovir for Inhibiting Mmtv-Like Viruses Involved in Breast Cancer and Primary Biliary Cirrhosis
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2008030605A2 (en) 2006-09-08 2008-03-13 The Regents Of The University Of Michigan Herv group ii viruses in lymphoma and cancer
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP1980568A1 (de) 2007-04-13 2008-10-15 Eberhard Karls Universität Tübingen Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8163707B2 (en) * 2008-09-15 2012-04-24 Enanta Pharmaceuticals, Inc. 4′-allene-substituted nucleoside derivatives
BRPI1010809A2 (pt) * 2009-05-12 2015-10-13 Southern Res Inst composto, composição farmacêutica, métodos de tratar câncer em mamífero e usos de compostos e de composição farmacêutica
WO2010135690A1 (en) 2009-05-21 2010-11-25 The Regents Of The University Of Michigan Antiviral treatment of lymphoma and cancer
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
EP2625292B1 (en) 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
DK2658399T4 (da) 2010-12-31 2024-03-25 Abbott Lab Ernæringssammensætninger omfattende humane mælkeoligosaccharider til anvendelse i behandling og/eller forebyggelse af enterisk rotavirus-infektion
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
US20120321637A1 (en) 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
GEP201706721B (en) * 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
HK1214270A1 (zh) 2012-10-29 2016-07-22 共晶制药股份有限公司 用於治療病毒感染和癌症的嘧啶核苷及其單磷酸酯前藥
EP2971120B1 (en) 2013-03-15 2018-06-06 Cold Spring Harbor Laboratory Transposon activation during aging and neuronal decline
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA033866B1 (ru) * 2014-02-06 2019-12-03 Рибосайенс Ллк 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
EP3137124B1 (en) 2014-04-29 2019-01-09 Microvention, Inc. Polymers including active agents
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
CA2955604A1 (en) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
PE20170673A1 (es) 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
AU2015320511B2 (en) 2014-09-26 2020-11-12 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of Respiratory Syncytial Virus RNA replication
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
FR3027804A1 (fr) 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
WO2016138425A1 (en) 2015-02-26 2016-09-01 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
WO2016149366A1 (en) 2015-03-16 2016-09-22 The Johns Hopkins University Methods and compositions for treating cancer
EP3317290A4 (en) 2015-07-02 2019-04-10 Spring Bank Pharmaceuticals, Inc. COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION
JP6767011B2 (ja) 2015-09-18 2020-10-14 ヤマサ醤油株式会社 抗ｄｎａウィルス活性などの生理活性を有するヌクレオシド誘導体
EP3355924A1 (en) 2015-09-29 2018-08-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of treating and preventing amyotrophic lateral sclerosis
WO2017142984A1 (en) 2016-02-16 2017-08-24 Riboscience Llc Inhibitors of zika virus
US10874683B2 (en) 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017222911A1 (en) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
WO2018093777A1 (en) 2016-11-15 2018-05-24 The Regents Of The University Of Michigan Centromere analysis
AU2018210001A1 (en) 2017-01-23 2019-08-01 Health Research, Inc. Inhibition of endogenous reverse transcriptase and targeting of cells for prophylaxis and therapy of cancer and aging
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018222774A1 (en) 2017-05-30 2018-12-06 Alios Biopharma, Inc. Methods for treating pneumoviruses
CN111971284A (zh) 2017-12-27 2020-11-20 埃默里大学 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
WO2019246376A1 (en) 2018-06-20 2019-12-26 Chernova Olga B Prevention of primary and treatment-resistant cancer by inhibitors of endogenous reverse transcriptase
US20220110963A1 (en) 2019-01-02 2022-04-14 The General Hospital Corporation Reverse transcriptase blocking agents and methods of using the same
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
CN113304166B (zh) 2020-02-27 2022-10-14 河南真实生物科技有限公司 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
EP4114409A4 (en) 2020-03-20 2024-08-07 University of Virginia Patent Foundation NRTIS, NRTI METABOLITES AND NRTI ANALOGUES FOR MACULAR DEGENERATION AND VIRAL INFECTIONS
TW202228724A (zh) 2020-09-23 2022-08-01 美商昂克萊亞製藥公司 以反轉錄酶抑制劑治療癌症之方法
KR20230107543A (ko) * 2020-09-23 2023-07-17 트랜스포손 테라퓨틱스, 인코포레이티드 질병을 치료하기 위한 line-1 억제제
KR20230157430A (ko) 2021-03-15 2023-11-16 트랜스포손 테라퓨틱스, 인코포레이티드 Cns 및 전신 질병을 치료하기 위한 line-1 억제제
MX2023011870A (es) 2021-04-09 2023-12-07 Univ Emory Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus.
US20240261317A1 (en) 2021-05-17 2024-08-08 Rome Therapeutics, Inc. Methods of treating medical conditions and inhibiting line1 reverse transcriptaseusing a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound
CN114288313B (zh) 2022-02-18 2023-07-04 常晓宇 嘧啶核苷类药物在制备预防或治疗冠状病毒感染性疾病药物中的用途

Also Published As

Publication number Publication date
KR20250004956A (ko) 2025-01-08
US20230295212A1 (en) 2023-09-21
CN119546620A (zh) 2025-02-28
AU2023236711A1 (en) 2024-10-03
TW202400134A (zh) 2024-01-01
EP4493573A1 (en) 2025-01-22
US20230374058A1 (en) 2023-11-23
CO2024012882A2 (es) 2024-10-10
WO2023178133A1 (en) 2023-09-21
IL315480A (en) 2024-11-01
CA3245459A1 (en) 2023-09-21
JP2025509635A (ja) 2025-04-11
US20250145654A1 (en) 2025-05-08
MX2024011291A (es) 2025-03-07
WO2023178133A9 (en) 2023-10-26
US12187758B2 (en) 2025-01-07

Similar Documents

Publication Publication Date Title
PE20250684A1 (es) Compuestos y metodos para el tratamiento de enfermedades
CO2021015067A2 (es) Compuestos antivirales que contienen nitrilo
JP7446993B2 (ja) 生物活性分子コンジュゲート、その調製法及び使用
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
ES2975330T3 (es) Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
BR112021026142A2 (pt) Composto conjugado ligado à cadeia lateral da fórmula, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos
ATE549334T1 (de) 7,8-dihydro-1,6-naphthyridin-5(6h)-one und verwandte bicyclische verbindungen als hemmer der dipeptidyl-peptidase iv sowie verfahren
WO2012107498A4 (en) Lysine demethylase inhibitors for myeloproliferative disorders
AR060089A1 (es) Tratamiento del dolor
RU2008138560A (ru) Улучшенные способы лечения опухолей
AR096526A1 (es) Agentes citotóxicos para el tratamiento del cáncer
MX2025002218A (es) Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3
US20220096641A1 (en) Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
CO2024015551A2 (es) Tratamiento de trastornos neurológicos
MX2022011904A (es) Aminociclobutanos como moduladores de monoacilglicerol lipasa.
CO2024007413A2 (es) Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CL2025002792A1 (es) Compuesto y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores
MA58327B2 (fr) Nouveau composé de [2-(diméthylamino)-2-phénylbutyl]-3,4,5-triméthoxybenzoate 4-méthyl-2н-chromen-2-one-7-ylsulfate et son utilisation
SG183657A1 (en) Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
AR127321A1 (es) Inhibidores de la monoacilglicerol lipasa (magl)
AR128566A1 (es) Combinaciones de fármacos y métodos para tratar el cáncer de ovario
PE20251687A1 (es) Compuestos y metodos para modular splicing